SUNRISE, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic ...
Transpire Bio's ANDA for Generic High-Strength Trelegy® Ellipta® Accepted for Filing by the U.S. FDA
SUNRISE, Fla., May 11, 2026 /PRNewswire/ -- Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company developing inhaled therapeutics for pulmonary and systemic diseases, today ...
SUNRISE, Fla., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, ...
SUNRISE, Fla., Aug. 11, 2026 /PRNewswire/ -- Transpire Bio Inc., an integrated, U.S.-based, clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and ...
WESTON, Fla., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated, clinical-stage biopharmaceutical company focused on developing inhaled medicines, today announced the company dosed the ...
NEW YORK--(BUSINESS WIRE)--CI&T (NYSE: CINT), a global digital specialist, announces today, as a complement to the market announcement of August 16, 2022, the completion of the acquisition of ...
SUNRISE, Fla., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results